Opinions
- Bob Mason
Trump brings democracy to its knees, weighing on the Greenback this week. There could be more twists and turns before Inauguration Day…
- Bob Mason
Vaccination rates are raising eyebrows, as new COVID-19 cases continue to spike. Failure to materially ramp up vaccinations should be of concern.
- Bob Mason
Trump signs the aid package and spending bill as lawmakers ready to override his Defence Bill veto.
- Bob Mason
Bitcoin had an impressive year in 2020, assuming there is no year-end meltdown. More of the same would deliver $100,000 for the bulls…
- Bob Mason
The EU continues to give the markets hope. Key hurdles remain, however, including access to UK fisheries. Is there really a resolution to this?
- Bob Mason
The Latest On Monday, the EU’s European Medicines Agency (“EMA”) recommended the authorization of the BioNTech/Pfizer Inc. vaccine. An assessment report, with details of the EMA’s evaluation of Comirnaty, and the full risk management plan is due out in the coming days. According to the EMA report, the recommendation was
- Bob Mason
Moderna Inc. and the FDA will be in focus, with AstraZeneca also in search of approval in the UK this week.
- Bob Mason
FDA feels the heat from the Whitehouse, as the U.S readies to begin Operation Warp. Vaccine availability will be an issue near-term, however.
- Bob Mason
A no-deal scenario the likely outcome. That’s the news of the day. The ever eternal optimists will be hoping for good news before the markets close…
- Bob Mason
The FDA is due to review BioNTech/Pfizer Inc.’s vaccine later today. Approval is a must to support riskier assets and give some hope to the worst affected.
- Bob Mason
The British PM and EU President agree to a Sunday deadline. Make or break talks will now continue and the Pound could come under fire…
- Bob Mason
It’s all eyes on Brussels, with British PM Johnson looking to salvage a Brexit deal. A failure to agree on a way forward would sink the Pound.
- Bob Mason
The Pound slides back to $1.32 levels off the back of gloomy Brexit updates. Pound sensitivity will be on the rise as time now rapidly runs out.
- Bob Mason
With the UK set to begin vaccinations this week and the FDA to review the Pfizer Inc. vaccine, production and logistics news will be of particular interest.
- Bob Mason
Are we in for one more Brexit shock?
- Bob Mason
The UK becomes the first nation to approve a COVID-19 vaccine and with an efficacy rate of 95%, an end to the pandemic may be in sight.
- Bob Mason
Time is running out and yet both sides stand firm on the remaining hurdles. The markets and the Pound continue to reflect optimism, however.
- Bob Mason
Moderna Inc. submits its EUA to the FDA, with both Pfizer Inc. and Moderna Inc. also submitting requests to the EMA.
- Bob Mason
AstraZeneca last week announced plans to launch a new global trial. Without the AstraZeneca vaccine, however, many nations will be without…
- Vladimir Zernov
There is some rotation from tech stocks into cyclical stocks.